• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MyMD Pharmaceuticals Inc. (Amendment)

    2/11/22 7:17:38 AM ET
    $MYMD
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYMD alert in real time by email
    SC 13G/A 1 ea155269-13ga2intra_mymdpha.htm AMENDMENT NO. 2 TO SCHEDULE 13G
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

    MyMD Pharmaceuticals, Inc.

     

    (Name of Issuer)

     

    Common Stock, no par value per share

     

    (Title of Class of Securities)

     

    62856X102

     

    (CUSIP Number)

     

    December 31, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 6

     

     

    CUSIP No. 62856X102  

     

    1. Names of Reporting Persons.
       
      Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power

    364,963

         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power

    364,963

           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 364,963 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 1.0% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 2 of 6

     

     

    CUSIP No. 62856X102  

     

    1. Names of Reporting Persons.
       
      Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization United States of America
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power 0
         
    6. Shared Voting Power 364,963
         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power

    364,963

           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 364,963 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 1.0% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      IN; HC  

     

    Page 3 of 6

     

     

    CUSIP No. 62856X102

     

    1. Names of Reporting Persons.
       
      Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)
       
      (a) ☐
      (b) ☐
    3. SEC Use Only
         
    4. Citizenship or Place of Organization Delaware
         

    Number of

    Shares Beneficially

    Owned by Each

    Reporting

    Person With:

    5. Sole Voting Power

    0

         
    6. Shared Voting Power

    364,963

         
    7. Sole Dispositive Power 0
         
    8. Shared Dispositive Power

    364,963

           
    9. Aggregate Amount Beneficially Owned by Each Reporting Person 364,963 (see Item 4)
         
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐
         
    11. Percent of Class Represented by Amount in Row (9) 1.0% (see Item 4)
         
    12. Type of Reporting Person (See Instructions)  
         
      OO  

     

    Page 4 of 6

     

     

    This Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) on November 20, 2020, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on January 29, 2021 (the “Schedule 13G”).

     

    Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

     

    Item 1.

     

    (a)Name of Issuer

     

    MyMD Pharmaceuticals, Inc. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    855 N. Wolfe Street, Suite 623

    Baltimore, MD 21205

    Item 2.

     

    (e)CUSIP Number

     

    62856X102

     

    Item 4. Ownership.

     

    (a)and (b):

     

    As of the close of business on December 31, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 364,963 shares of Common Stock, which consisted of (i) 98 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 1”) and (ii) 364,865 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 2”), and all such shares of Common Stock in the aggregate represented beneficial ownership of approximately 1.0% of the Common Stock, based on (1) 37,648,020 shares of Common Stock outstanding as of November 8, 2021 as reported by the Issuer, plus (2) 98 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (3) 364,865 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2.

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 364,963.

     

    (iii)Sole power to dispose or to direct the disposition of 0.

     

    (iv)Shared power to dispose or to direct the disposition of 364,963.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 11, 2022

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

      

    Page 6 of 6

    Get the next $MYMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MYMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MYMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today

      New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) (formerly MyMD Pharmaceuticals, Inc.) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced that its common stock, listed on the Nasdaq Capital Market, begins trading under the new ticker symbol, "TNFA," effective before the market open today, July 24, 2024. The new trading symbol "TNFA" replaces the Company's previous trading symbol "MYMD" and coincides with the Company's previously announced corporat

      7/24/24 9:05:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

      New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clinical trials of TNF-alpha inhibitor drug MYMD-1® following statistically significant Phase 2 studies TNF Pharmaceuticals will begin trading on Nasdaq under the new trading symbol "TNFA" effective July 24, 2024 TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) (the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name "TNF Pharmaceuticals, Inc.," effective today. The Company's com

      7/22/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Friscia Stephen

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      6/28/24 4:05:18 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Pharmacyte Biotech, Inc.

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/30/24 4:05:04 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Glass Mitchell

      3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)

      5/16/24 5:30:25 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    SEC Filings

    See more
    • SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.

      DEF 14A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      7/1/24 5:15:16 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/24/24 4:23:01 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-3 filed by MyMD Pharmaceuticals Inc.

      S-3 - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)

      6/21/24 5:14:29 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

      Dr. Glass brings a 35-year career in life sciences with multiple drug approvals including Accolate ®, Avandia ® and Coreg® Dr. Glass brings broad expertise in regulatory strategies: 5 NDAs and MAAs, 7 pre-NDA meetings, 12 End of Phase 2 meetings, and more than 80 INDs Company announces President and CMO transition as clinical development advances through mid-stage trials Company also appoints new independent board member, Mr. Stephen Friscia, an experienced investment strategist MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflamm

      6/17/24 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board

      MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that it has appointed David Rini to the Company's Scientific Advisory Board. "I am delighted to join the MyMD Scientific Advisory Board and look forward to working on the development and communication about our two platforms," stated David Rini. David Rini is a Professor at the Johns Hopkins University School of Medicine in the Department of Art of Applied to Medicine, Cellular and Molecular Medicine, and Director of the Medical and Biological Illustration Graduate Program. Professor Rini earned his M

      5/17/21 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by MyMD Pharmaceuticals Inc.

      SC 13D - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      5/30/24 4:05:03 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by MyMD Pharmaceuticals Inc.

      SC 13G - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 3:13:35 PM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by MyMD Pharmaceuticals Inc. (Amendment)

      SC 13G/A - MyMD Pharmaceuticals, Inc. (0001321834) (Subject)

      2/14/24 11:27:33 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYMD
    Financials

    Live finance-specific insights

    See more
    • MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

      MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a conference call today, August 2nd, at 4:30pm ET to discuss the results. To participate in the conference call, please register here. A webcast can also be accessed under the ‘Events & Presentations' section on the Investors page at w

      8/2/23 8:30:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

      - MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) - First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets - Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutica

      7/31/23 9:00:00 AM ET
      $MYMD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care